View Financial HealthOSR Holdings 배당 및 자사주 매입배당 기준 점검 0/6OSR Holdings 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-43.0%자사주 매입 수익률총 주주 수익률-43.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • May 14First quarter 2026 earnings released: US$0.09 loss per share (vs US$1.05 loss in 1Q 2025)First quarter 2026 results: US$0.09 loss per share (improved from US$1.05 loss in 1Q 2025). Net loss: US$2.93m (loss narrowed 74% from 1Q 2025).공시 • May 12OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026. Location: washington, seattle, United StatesNew Risk • Apr 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 18% over the past year. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$37m net loss next year). Revenue is less than US$5m (US$2.9m revenue). Market cap is less than US$100m (US$24.7m market cap).공시 • Mar 10OSR Holdings, Inc. Receives Additional Compliance Period to Regain Compliance with Nasdaq Listing RuleOn March 5, 2026, OSR Holdings, Inc. (the Company) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. As previously disclosed, on September 5, 2025, the Company received notice from Nasdaq that the closing bid price of the Company's common stock had fallen below the required minimum bid price of $1.00 per share for 30 consecutive business days and that the Company had been provided an initial 180 calendar day compliance period, or until March 4, 2026, to regain compliance. Nasdaq determined that the Company is eligible for the additional compliance period because the Company meets the continued listing requirement for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the minimum bid price requirement. If at any time during this additional compliance period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance with the minimum bid price requirement. The Company intends to monitor the closing bid price of its common stock and will consider available options to regain compliance with Nasdaq's minimum bid price requirement.Board Change • Dec 31High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. No highly experienced directors. Chief Legal Officer & Director Jun Whang is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Sep 11OSR Holdings, Inc. Receives A Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price RequirementOn September 5, 2025, OSR Holdings, Inc. (the Company") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the Company's securities, which will continue to trade on The Nasdaq Capital Market under the symbols OSRH" and OSRHW." The Company has been provided an initial period of 180 calendar days, or until March 4, 2026, to regain compliance. If at any time during this period the closing bid price of the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance. If the Company does not regain compliance by March 4, 2026, it may be eligible for an additional 180-day compliance period, provided that it meets the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market (other than the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency, including by means of a reverse stock split if necessary. If the Company is not eligible for the second compliance period, Nasdaq will provide notice that the Company's securities are subject to delisting, which determination the Company may appeal. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Nasdaq Listing Rules.New Risk • Aug 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 31% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.8m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Revenue has declined by 48% over the past year. Shareholders have been substantially diluted in the past year (434% increase in shares outstanding). Revenue is less than US$1m (US$105k revenue). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (US$11.1m market cap).공시 • Aug 20OSR Holdings, Inc., Annual General Meeting, Sep 17, 2025OSR Holdings, Inc., Annual General Meeting, Sep 17, 2025. Location: 5 penn plaza, 19th floor, new york 1001., new york United StatesReported Earnings • Aug 19Second quarter 2025 earnings released: EPS: US$0.02 (vs US$1.83 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.02 (up from US$1.83 loss in 2Q 2024). Net income: US$331.4k (up US$3.79m from 2Q 2024).공시 • Jul 02OSR Holdings, Inc. Announces Resignation of Sang Hyun Kim as A Member of the Board of DirectorsOSR Holdings, Inc. announced that on June 26, 2025, Sang Hyun Kim provided notice of his resignation as a member of the Board of Directors, including his role as an independent director of the company. Mr. Kim’s resignation took immediate effect and was not the result of any dispute or disagreement with the Company on any matter relating to its operations, policies or practices.공시 • May 16OSR Holdings, Inc. announced delayed 10-Q filingOn 05/15/2025, OSR Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 24OSR Holdings, Inc. Auditor Raises 'Going Concern' DoubtOSR Holdings, Inc. filed its 10-K on Apr 22, 2025 for the period ending Dec 31, 2024. In this report its auditor, WithumSmith+Brown, PC , gave an unqualified opinion expressing doubt that the company can continue as a going concern.공시 • Apr 04OSR Holdings, Inc. announced that it expects to receive $80 million in fundingOSR Holdings, Inc. entered into purchase agreement to sell common stock up to gross proceeds $80,000,000 on April 3, 2025. The transaction includes participation from White Lion GBM Innovation Fund.공시 • Mar 25OSR Holdings, Inc. Appoints Constance Höfer as Chief Scientific OfficerOSR Holdings, Inc. announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based therapies. Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless transition from early-stage research to successful clinical development. Dr. Höfer's appointment reinforces OSR Holdings' commitment to advancing cutting-edge therapeutic solutions and strengthening its R&D capabilities. Her expertise will enhance the company's ability to identify and develop promising drug candidates, streamline clinical development, and improve regulatory success rates. By leveraging her experience in biologics, small molecules, and other advanced therapeutic modalities, OSR Holdings aims to accelerate the translation of innovative research into clinical applications, expand its footprint in oncology and immunology, and drive long-term value for both patients and stakeholders.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 OSRH 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: OSRH 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장OSR Holdings 배당 수익률 vs 시장OSRH의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (OSRH)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.5%분석가 예측 (OSRH) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 OSRH 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 OSRH 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 OSRH 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: OSRH 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 14:16종가2026/06/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스OSR Holdings, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Andrew WhiteEmerging Growth Research LLC
Reported Earnings • May 14First quarter 2026 earnings released: US$0.09 loss per share (vs US$1.05 loss in 1Q 2025)First quarter 2026 results: US$0.09 loss per share (improved from US$1.05 loss in 1Q 2025). Net loss: US$2.93m (loss narrowed 74% from 1Q 2025).
공시 • May 12OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026OSR Holdings, Inc., Annual General Meeting, Jun 18, 2026. Location: washington, seattle, United States
New Risk • Apr 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 18% over the past year. Shareholders have been substantially diluted in the past year (72% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$37m net loss next year). Revenue is less than US$5m (US$2.9m revenue). Market cap is less than US$100m (US$24.7m market cap).
공시 • Mar 10OSR Holdings, Inc. Receives Additional Compliance Period to Regain Compliance with Nasdaq Listing RuleOn March 5, 2026, OSR Holdings, Inc. (the Company) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that Nasdaq has granted the Company an additional 180 calendar day period, or until August 31, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. As previously disclosed, on September 5, 2025, the Company received notice from Nasdaq that the closing bid price of the Company's common stock had fallen below the required minimum bid price of $1.00 per share for 30 consecutive business days and that the Company had been provided an initial 180 calendar day compliance period, or until March 4, 2026, to regain compliance. Nasdaq determined that the Company is eligible for the additional compliance period because the Company meets the continued listing requirement for the market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the minimum bid price requirement. If at any time during this additional compliance period the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance with the minimum bid price requirement. The Company intends to monitor the closing bid price of its common stock and will consider available options to regain compliance with Nasdaq's minimum bid price requirement.
Board Change • Dec 31High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 1 experienced director. No highly experienced directors. Chief Legal Officer & Director Jun Whang is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Sep 11OSR Holdings, Inc. Receives A Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price RequirementOn September 5, 2025, OSR Holdings, Inc. (the Company") received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement set in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The notice has no immediate effect on the listing or trading of the Company's securities, which will continue to trade on The Nasdaq Capital Market under the symbols OSRH" and OSRHW." The Company has been provided an initial period of 180 calendar days, or until March 4, 2026, to regain compliance. If at any time during this period the closing bid price of the Company's common stock is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation that the Company has regained compliance. If the Company does not regain compliance by March 4, 2026, it may be eligible for an additional 180-day compliance period, provided that it meets the continued listing requirements for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market (other than the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency, including by means of a reverse stock split if necessary. If the Company is not eligible for the second compliance period, Nasdaq will provide notice that the Company's securities are subject to delisting, which determination the Company may appeal. The Company intends to actively monitor the closing bid price of its common stock and will consider available options to regain compliance with the Nasdaq Listing Rules.
New Risk • Aug 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 31% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$1.8m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Revenue has declined by 48% over the past year. Shareholders have been substantially diluted in the past year (434% increase in shares outstanding). Revenue is less than US$1m (US$105k revenue). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (US$11.1m market cap).
공시 • Aug 20OSR Holdings, Inc., Annual General Meeting, Sep 17, 2025OSR Holdings, Inc., Annual General Meeting, Sep 17, 2025. Location: 5 penn plaza, 19th floor, new york 1001., new york United States
Reported Earnings • Aug 19Second quarter 2025 earnings released: EPS: US$0.02 (vs US$1.83 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.02 (up from US$1.83 loss in 2Q 2024). Net income: US$331.4k (up US$3.79m from 2Q 2024).
공시 • Jul 02OSR Holdings, Inc. Announces Resignation of Sang Hyun Kim as A Member of the Board of DirectorsOSR Holdings, Inc. announced that on June 26, 2025, Sang Hyun Kim provided notice of his resignation as a member of the Board of Directors, including his role as an independent director of the company. Mr. Kim’s resignation took immediate effect and was not the result of any dispute or disagreement with the Company on any matter relating to its operations, policies or practices.
공시 • May 16OSR Holdings, Inc. announced delayed 10-Q filingOn 05/15/2025, OSR Holdings, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 24OSR Holdings, Inc. Auditor Raises 'Going Concern' DoubtOSR Holdings, Inc. filed its 10-K on Apr 22, 2025 for the period ending Dec 31, 2024. In this report its auditor, WithumSmith+Brown, PC , gave an unqualified opinion expressing doubt that the company can continue as a going concern.
공시 • Apr 04OSR Holdings, Inc. announced that it expects to receive $80 million in fundingOSR Holdings, Inc. entered into purchase agreement to sell common stock up to gross proceeds $80,000,000 on April 3, 2025. The transaction includes participation from White Lion GBM Innovation Fund.
공시 • Mar 25OSR Holdings, Inc. Appoints Constance Höfer as Chief Scientific OfficerOSR Holdings, Inc. announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions at Sandoz Biopharmaceuticals, Priaxon AG, and Medigene AG, playing a key role in advancing therapeutic programs across various modalities, including New Biological Entities (NBEs), New Chemical Entities (NCEs), nucleotides, and viral and cell-based therapies. Coupled with her extensive industry experience and a PhD in Pharmacology from the University of Newcastle, Dr. Höfer has a strong foundation in clinical pharmacology and translational medicine, ensuring a seamless transition from early-stage research to successful clinical development. Dr. Höfer's appointment reinforces OSR Holdings' commitment to advancing cutting-edge therapeutic solutions and strengthening its R&D capabilities. Her expertise will enhance the company's ability to identify and develop promising drug candidates, streamline clinical development, and improve regulatory success rates. By leveraging her experience in biologics, small molecules, and other advanced therapeutic modalities, OSR Holdings aims to accelerate the translation of innovative research into clinical applications, expand its footprint in oncology and immunology, and drive long-term value for both patients and stakeholders.